U
SLXP

UBS’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

UBS’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$78K Sell
500
-200
-29% -$29K ﹤0.01% 6293
2014
Q2 		$86K Sell
700
-4,900
-88% -$542K ﹤0.01% 6129
2014
Q1 		$580K Buy
5,600
+5,300
+1,767% +$543K ﹤0.01% 4077
2013
Q4 		$27K Sell
300
-500
-63% -$39.9K ﹤0.01% 7799
2013
Q3 		$53K Buy
800
+600
+300% +$41.3K ﹤0.01% 6802
2013
Q2 		$13K Buy
+200
New +$11.4K ﹤0.01% 8404

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's SLXP Position: Q3 2014 in Review

UBS increased its SALIX PHARMACEUTICALS LTD DEL (SLXP) stake by 31% in Q3 2014, buying an estimated $1.94M and bringing the position to 56,648 shares worth $8.85M. The position accounts for 0.01% of the portfolio, ranked #1548.

UBS first reported a position in SLXP in Q2 2013 and has held it in 6 quarters since. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • UBS held 56,648 shares of SALIX PHARMACEUTICALS LTD DEL worth $8.85M as of Q3 2014.
  • UBS bought 13,384 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $1.94M.
  • SALIX PHARMACEUTICALS LTD DEL made up 0.01% of UBS's portfolio in Q3 2014, its #1548 holding.
  • UBS first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and has held it in 6 quarters since.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.